This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Christoph Reisser, MD; Uwe Haberkorn, MD; Antonia Dimitrakopoulou-Strauss, MD; Eberhard Seifert, MD; Ludwig G. Strauss, MD

Arch Otolaryngol Head Neck Surg. 1995;121(3):272-276.

Abstract
Objective
Antineoplastic chemotherapy in cases of nonresectable advanced malignancies of the head and neck can be very debilitating for the patient. For individual treatment planning, it is important to evaluate the early clinical effect of therapy. Morphological parameters, such as the size of the tumor and its relationship to adjacent structures, which can be determined by a number of imaging procedures, hardly reflect early therapeutic effects. Therefore, the metabolic activity of the tumor should be studied during antineoplastic therapy.

Design
Positron emission tomography was performed in 12 patients with metastasizing squamous cell carcinomas of the oropharynx, hypopharynx, and larynx before and after the first chemotherapeutic cycle.

Results
The fludeoxyglucose F 18 uptake was increased in all tumors and lymph nodes. In most lesions, an obvious response to treatment was observed after the first cycle of chemotherapy. However, differences in metabolic activity and changes in metabolism occurred during therapy. The treatment response varied in different lymph nodes in the same patient. There was a linear relation between metabolic change and growth rate during therapy, with different regression functions for tumors and lymph node metastases.

Conclusions
Positron emission tomography provides absolute and comparable quantitative data on tumor metabolism before and after chemotherapy. It is therefore a useful method for observation and possible improvement of therapeutic measures in patients undergoing systemic chemotherapy.

(Arch Otolaryngol Head Neck Surg. 1995;121:272-276)

Author Affiliations
From the Departments of Otorhinolaryngology, University of Heidelberg (Dr Reisser) and University of Heidelberg-Mannheim (Dr Seifert), and the Institute of Radiology and Pathophysiology, German Cancer Research Center (Drs Haberkorn, Dimitrakopoulou-Strauss, and Strauss), Heidelberg, Germany.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

PET in the Assessment of Therapy Response in Patients with Carcinoma of the Head and Neck and of the Esophagus
Kostakoglu and Goldsmith
JNM 2004;45:56-68.
ABSTRACT | FULL TEXT  

Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy
Smith et al.
JCO 2000;18:1676-1688.
ABSTRACT | FULL TEXT  

Preliminary Experience With Thallous Chloride Tl 201--Labeled Single-Photon Emission Computed Tomography Scanning in Head and Neck Cancer
Theo Gregor et al.
Arch Otolaryngol Head Neck Surg 1996;122:509-514.
ABSTRACT